Rationale and evidence for the incorporation of heparin into the diclofenac epolamine medicated plaster

Abstract

Objective: The nonsteroidal anti-inflammatory drug (NSAID) diclofenac epolamine (DHEP) formulated as a topical patch has demonstrated efficacy and safety in the localized treatment of acute pain from minor strains, sprains and contusions, and for epicondylitis and knee osteoarthritis. The glycosaminoglycan heparin enhances the activity of topical NSAIDs formulated as a medicated plaster, even in the absence of any significant release of heparin. Therefore, DHEP plus, a new formulation of the DHEP medicated plaster containing a small amount of heparin sodium as excipient, has been developed.

Methods: We reviewed the pivotal and supportive studies of the clinical development program of the new patch and evaluated the role of heparin as an enhancer in the treatment of localized pain/inflammation of musculoskeletal structures, associated with post-traumatic and/or rheumatic conditions.

Results: The data was consistent with the concept that heparin increased the clinical activity of the DHEP plus medicated plaster versus the reference DHEP medicated plaster through improved bioavailability due to enhanced movement of diclofenac from the plaster. Both DHEP formulations have the same dissolution profile, indicating that heparin does not change the physical and chemical characteristics of the plaster. Permeation testing showed that heparin is not released from the DHEP plus medicated plaster. Efficacy studies showed that the DHEP plus medicated plaster was significantly more effective in reducing pain than the reference marketed DHEP medicated plaster.

Conclusions: The benefit/risk assessment of DHEP plus 180 mg medicated plaster is favorable, with a safety profile equal to placebo and improved efficacy over the reference marketed DHEP medicated plaster.

Keywords:

• Nonsteroidal anti-inflammatory drugs
• diclofenac epolamine patch
• heparin
• excipients
• pain

Transparency

Declaration of funding

This paper was not funded.

Declarations of financial/other relationships

A.N. and C.J. have disclosed that they are employees of IBSA. K.D.R. and M.S.R. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgements

We thank Ray Hill, an independent medical writer, who provided medical writing support on behalf of Health Publishing & Services Srl. IBSA Institut Biochimique SA funded this assistance.

Notes

* Flector, Flectormed, Flectorin, Flectopar, Flalgo, and Weavor are registered trademarks of IBSA Institut Biochimique SA.